Search research articles
Contact Us
Filters
Showing results (21-30 of 71) with videos related to
Page
of 8
Sort By:
Journal of Managed Care & Specialty Pharmacy
|
March 25, 2021
Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies
Swetha R Palli, Bin Xie, Benjamin Chastek, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 16, 2020
Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers
David Singer, Lindsay G S Bengtson, Caitlin Elliott, et al.
Geobiology
|
September 13, 2014
Deep-biosphere consortium of fungi and prokaryotes in Eocene subseafloor basalts
S Bengtson, M Ivarsson, A Astolfo, et al.
Journal of Cardiology
|
March 22, 2017
Questions in the comparative effectiveness of dabigatran and warfarin in atrial fibrillation
Alvaro Alonso, Pamela L Lutsey, Lin Y Chen, et al.
Journal of Managed Care & Specialty Pharmacy
|
December 4, 2025
Clinical and economic burden of chronic kidney disease in Medicare Fee-for-Service beneficiaries with and without comorbid type 2 diabetes and heart failure: A retrospective cohort study
Lydia Yejin Lee, Andrew J Epstein, Satabdi Chatterjee, et al.
Journal of Medical Economics
|
April 8, 2020
Economic impact of cardiac implantable electronic device infections: cost analysis at one year in a large U.S. health insurer
Elizabeth L Eby, Lindsay G S Bengtson, Michael P Johnson, et al.
BMC Public Health
|
March 19, 2026
Association between access to care and direct healthcare costs in people with and at high-risk of chronic kidney disease in the United States: a pooled cross-sectional study using the Medical Expenditure Panel Survey
Satabdi Chatterjee, Thomas Flottemesch, Lindsay G S Bengtson, et al.
Journal of Cardiology
|
November 28, 2016
Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation
Lindsay G S Bengtson, Pamela L Lutsey, Lin Y Chen, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
March 31, 2023
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA
Nicola A Hanania, Scott H Bunner, Lindsay G S Bengtson, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
February 14, 2022
Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD
Surya P Bhatt, Cori Blauer-Peterson, Erin K Buysman, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 71) with videos related to
Sort By:
Page
of 8
Journal of Managed Care & Specialty Pharmacy
|
March 25, 2021
Comparison of COPD health care utilization and associated costs across patients treated with LAMA+LABA fixed-dose therapies
Swetha R Palli, Bin Xie, Benjamin Chastek, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
December 16, 2020
Healthcare Resource Utilization, Exacerbations, and Readmissions Among Medicare Patients with Chronic Obstructive Pulmonary Disease After Long-Acting Muscarinic Antagonist Therapy Initiation with Soft Mist versus Dry Powder Inhalers
David Singer, Lindsay G S Bengtson, Caitlin Elliott, et al.
Geobiology
|
September 13, 2014
Deep-biosphere consortium of fungi and prokaryotes in Eocene subseafloor basalts
S Bengtson, M Ivarsson, A Astolfo, et al.
Journal of Cardiology
|
March 22, 2017
Questions in the comparative effectiveness of dabigatran and warfarin in atrial fibrillation
Alvaro Alonso, Pamela L Lutsey, Lin Y Chen, et al.
Journal of Managed Care & Specialty Pharmacy
|
December 4, 2025
Clinical and economic burden of chronic kidney disease in Medicare Fee-for-Service beneficiaries with and without comorbid type 2 diabetes and heart failure: A retrospective cohort study
Lydia Yejin Lee, Andrew J Epstein, Satabdi Chatterjee, et al.
Journal of Medical Economics
|
April 8, 2020
Economic impact of cardiac implantable electronic device infections: cost analysis at one year in a large U.S. health insurer
Elizabeth L Eby, Lindsay G S Bengtson, Michael P Johnson, et al.
BMC Public Health
|
March 19, 2026
Association between access to care and direct healthcare costs in people with and at high-risk of chronic kidney disease in the United States: a pooled cross-sectional study using the Medical Expenditure Panel Survey
Satabdi Chatterjee, Thomas Flottemesch, Lindsay G S Bengtson, et al.
Journal of Cardiology
|
November 28, 2016
Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation
Lindsay G S Bengtson, Pamela L Lutsey, Lin Y Chen, et al.
International Journal of Chronic Obstructive Pulmonary Disease
|
March 31, 2023
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA
Nicola A Hanania, Scott H Bunner, Lindsay G S Bengtson, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)
|
February 14, 2022
Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD
Surya P Bhatt, Cori Blauer-Peterson, Erin K Buysman, et al.
Page
of 8